Dulaglutide
GLP-1 receptor agonist Fc fusion protein
A GLP-1 analog fused to an antibody fragment, giving a long half-life and weekly dosing in published studies.
How it works
The Fc fusion slows renal clearance, sustaining GLP-1 receptor activation across a full week and producing steady glucose-dependent insulin release.
What research has shown
Cardiovascular outcome literature reports HbA1c reductions around 1.1 to 1.5% with modest weight reduction relative to other incretins.
Reported ranges in the literature
Low end
0.75 mg weekly
Optimal
1.5 mg weekly
High end
3.0 to 4.5 mg weekly in dose-ranging studies
Frequency reported in the literature: Once weekly
Protocol duration and pairing
Typical study duration
52 to 104 weeks in cardiovascular and glycemic outcome trials.
Best paired with
Studied mostly as monotherapy; combination data is limited to oral agents rather than other peptides.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.